1. INTRODUCTION 1.1. Allosteric Modulation: A Historical Perspective. Early ideas regarding allosterism emerged over 50 years ago but gained little traction in the receptor field because of limitations in molecular pharmacology and screening technology.
1,2
Allosterism is a critical biochemical mechanism, as it enables proteins to sense changes in their environment and to respond to them; Fenton has recently referred to this as "second secret of life", preceded only by the genome.
1−3 The term "allostery" comes from the Greek allos (αλλος), "other", and stereos (στερεoς), "solid (object)", meaning that an allosteric site of a regulatory protein is physically distinct from the classic, active, site.
1−8 In terms of receptor-based small molecule drug discovery, the binding site for the endogenous ligand is referred to as the orthosteric site.
1,4−8 In this setting, an allosteric modulator is a small molecule that binds at a topographically distinct allosteric site and either potentiates or inhibits the binding and/or signaling of an orthosteric ligand.
1,4−8 Fueled by the clinical success of the first allosteric modulator drugs 1−4 (benzodiazepines, referred to as "benzo" or BZD), which potentiate the effect of the neurotransmitter γ-aminobutyric acid (GABA) at the ionotropic GABA A receptor, the concept of allosteric modulation for a wide range of molecular targets has gained momentum in modern drug discovery (Figure 1 ). 4, 9 Benzodiazepines, for example, possess a number of modes of pharmacology and include positive allosteric modulators (PAMs), which potentiate GABA A receptor response, and negative allosteric modulators (NAMs), which decrease channel activity and modulate the ability of these GABAergic receptors to elicit sedative, hypnotic, and anxiolytic effects. In addition to PAMs and NAMs, silent allosteric modulators (SAMs, or neutral allosteric ligands) bind at allosteric sites and can block the activity of PAMs and NAMs but importantly have no effect on orthosteric ligand responses. In contrast to the potentially deadly effects of direct acting GABA A agonists, allosteric modulation of GABA A by the benzodiazepine class has proven to be clinically safe and effective. 4, 9 With advances in molecular pharmacology and screening technology, allosteric modulators have now been developed for other ion channels, kinases, phospholipases and seven transmembrane spanning receptors (7TMRs, also known as G-protein-coupled receptors (GPCRs)).
1,4−8,10−15 1.2. 7TMR Structures and Ligands. 7TMRs are the largest class of cell surface receptors, accounting for over 30% of currently marketed drugs and over 50% of all known drugs. 4−7 7TMRs are plasma membrane proteins that receive stimuli (in the form of hormones, neurotransmitters, light, ions, or odorants) on the extracellular surface to alter receptor conformation, which in turn activates signaling cascades and effector systems located within the intracellular cytosol via coupling to G proteins and other accessory proteins.
4−7 Much of our understanding of the basic structure and function of 7TMRs is based on biochemical, genetic, imaging, and molecular pharmacological research, as crystal structures of 7TMRs (rhodopsin, opsin, β2 and β1 (agonist and antagonist bound), dopamine D 3 , adenosine 2A (agonist and antagonist bound), chemokine CXCR 4 , histamine H 1 ) have only recently been solved definitively. 4−7,16−32 However, these crystal structures have powered the development of homology models for multiple 7TMRs and afforded avenues for ligand design efforts. Structurally, all 7TMRs possess seven transmembrane helices, three extracellular and three intracellular loops, with an extracellular N-terminal tail and an intracellular C-terminal tail (Figure 2) . 4−7,16−32 The heptahelical transmembrane domain is largely hydrophobic, whereas the extracellular (e1−e3) and intracellular (i1−i3) segments, or loops, are Figure 1 . Benzodiazepines, the first allosteric modulators with clinical success and marketed as GABA A allosteric modualtors. A generic benzodiazepine scaffold 1 highlighting the classical substitution patterns is shown. 2 (Librium) was the first benzodiazepine launched by Hoffmann-La Roche in 1960, and many other congeners followed such as 3 (Valium) and the tricylic analogue 4 (Xanax).
generally hydrophilic, as would be anticipated for amino acids exposed to the phospholipid-rich membrane and the water-rich environments, respectively. The seven transmembrane helices are each approximately two-dozen amino acids long, while the C-and N-terminal tails as well as the loops can vary widely in length with up to hundreds of amino acids. 4−7,16−32 On the basis of sequence homology and functional roles, 7TMRs commonly are divided into three main families (or classes): A (e.g., M 1 mAChR), B (e.g., CRF 1 ), and C (e.g., mGlu 5 ) (Figure 2 ). The families are readily distinguished by comparing their amino acid sequences. Family B is distinguished from family A by the presence of a larger extracellular loop, and family C has a large, bi-lobed N-terminal Venus fly trap (VFT) domain. A second major difference between the families concerns the location of the orthosteric binding site and the nature of the orthosteric ligand. As shown in Figure 2 , the orthosteric binding site of many family A 7TMRs is located with the 7TM domain whereas the orthosteric binding site is located in the large extracellular loop within family B and within the VFT domain in family C. The orthosteric ligands for families A and C are neurotransmitters, for example, 5 (acetylcholine, for the mAChRs) and 9 (glutamate, for the mGluRs), respectively. 4−7 The orthosteric ligands for family B 7TMRs are large peptide ligands with usually >30 amino acids, such as the 41 amino acid peptide 7 (hCRF) for corticotrophin releasing factor 1 (CRF 1 ). In contrast, allosteric ligands are structurally distinct from orthosteric ligands and bind at distinct sights, often, but not always, topologically distant from the orthosteric site.
4−7 For example, the family A M 1 mAChR PAM 6 (BQCA) 33 is believed to bind in a region above the TMs among the extracellular loops, whereas the family B PAM, 8 (DMP696), 34 and the family C NAM, 10 (MPEP), 35, 36 bind within the TM domains.
Are there naturally occurring allosteric modulators? This question is invariably posed during any discussion of allosteric modulators, and one must understand the complexity of identifying such ligands within the chemical diversity of ligands within the human body.
1,2,37 However, a few natural allosteric modulators have been described, including the unnatural amino acid D-serine (an allosteric modulator of the NMDA receptor), 38 L-phenylalanine, and L-tryptophan (allosteric modulators of the calcium receptor) 39 and the tetrepeptide Leu-Ser-Ala-Leu, also known as 5-HT moduline (an allosteric modulator of the 5-HT 1B receptor). 40, 41 1.3. Orthosteric and Allosteric 7TMR Pharmacology. Historically, almost all of the FDA-approved drugs that act at 7TMRs bind at the orthosteric site and regulate receptor function by classical agonism (directly stimulating a receptor response), inverse agonism (blocking constitutive receptor activity), or competitive antagonism (blocking the binding of the native agonist).
4−8 This is somewhat expected, as the many of these ligands were discovered by employing assays that biased targeting of the orthosteric binding site. Despite this success, synthetic ligands exist for only a fraction of the known 7TMRs, and many efforts have failed to produce highly selective compounds suitable as drug leads because of the highly conserved orthosteric binding site across a family of 7TMRs and/or because of unfavorable physicochemical and drug metabolism/ pharmacokinetic (DMPK) properties of synthetic orthosteric ligands. In many cases, direct acting agonists are toxic or lead to receptor desensitization, internalization, or down-regulation due to being "turned on" for prolonged periods.
4−8
In recent years, extraordinary progress has been made in the discovery, chemical optimization, pharmacological understanding, and in some cases, clinical development of allosteric modulators for multiple 7TMRs to treat a wide range of peripheral and CNS pathologies (Tables 1−3) . 4−8,10,11,42−180 This is due in large part to the development of functional assays that allow discovery of ligands that modulate a receptor without regard to the binding site and in effect identify ligands that do not bind at the orthosteric site. These new allosteric ligands include PAMs, NAMs, SAMs, as well as allosteric agonists (allosteric compounds that activate the receptor in the absence of the orthosteric ligand), partial antagonists (ligands that fully occupy the NAM site but only partially block receptor signaling), and ago-PAMs (PAMs that have inherent allosteric agonist activity). 4−8,10,11,42−44 However, many reported "allosteric" agonists may actually be "bitopic" ligands, that is, hybrid orthosteric/allosteric ligands that bind to both the orthosteric and allosteric sites within a given 7TMR. 181−183 Allosteric ligands offer numerous advantages: (1) Allosteric binding sites may be under less evolutionary pressure for their conservation, thus enabling high subtype selectivity to be achieved. (2) The effects of an allosteric modulator are saturable; once allosteric sites are occupied, no additional effects are observed, i.e., a "ceiling effect" (this is in contrast to "ceiling" of a partial agonist that will vary with receptor density and stimulus response coupling; this is thus far more variable than a ceiling level driven by cooperativity (at the level of binding; i.e., an α of 10 sets a limit of 10, whereas a partial agonist can scale up to a full agonist or down to an antagonist depending on the tissue and the disease)). (3) A modulator that lacks agonistic activity will only exert its effects when the endogenous agonist is present, resulting in temporal and spatial activity (also referred to as state dependence) of the endogenous ligand and (4) improved chemical tractability. 4−8 While the majority of these advantages over orthosteric ligands have been realized, allosteric modulation is far from a panacea for drug discovery, and there are many caveats to consider. First, the lack of evolutionary pressure on allosteric sites can, and has, lead to significant species differences, which complicates preclinical pharmacodynamic and safety studies in mice/rats/dogs if a primary assay employs recombinant human receptor or vice versa. [4] [5] [6] [7] [8] 10, 11 Second, the state dependence of allosteric modulators could be a liability in degenerative pathologies because of the progressive loss of endogenous orthosteric tone. For example, Alzheimer's disease is characterized by a decrease in cholinergic tone with disease progression, potentially rendering an mAChR PAM ineffective over time, as there is no acetycholine to potentiate. In these situations, an allosteric agonist might prove to be more optimal for disorders in which the orthosteric ligand is lost as the disease progresses. 4−8,10,11,42−44,181−183 By their very nature, allosteric ligands promote distinct conformations of 7TMRs such that the interactive properties of the receptor toward orthosteric ligands, as well as intracellular cytosolic proteins, can be modified in a ligand-and signaling protein-specific manner. This phenomenon has been termed "probe dependence" 184 and has substantial implications for the functional characterization and classification of allosteric modulators, as well as challenges associated with assigning quantitative parameters to facilitate allosteric ligand SAR. For example, the allosteric modulator 11 (LY2033298) positively modulates the binding affinity of the orthosteric agonist, ACh at the M 4 muscarinic receptor, but is neutral when tested against the orthosteric antagonist 12 ([ 3 H]-QNB). 90 Use of the endogenous agonist in a compound screen would thus reveal the allosteric activity of a ligand such as 11, whereas a radioligand-based screen using 12 as the probe would fail to identify 11 ( Figure 3 ). This highlights the requirement for careful consideration in the choice of orthosteric ligands to assess the effects of an allosteric modulator. Although the endogenous agonist for a given 7TMR should be the orthosteric probe of choice, this may not always be possible because of issues such as compound stability or in situations such as screening for ligands for orphan 7TMRs where the endogenous agonist is not known. In these cases, the use of a surrogate orthosteric probe is common, but the ensuing pharmacology may prove to be misleading because of the potential for differential probe dependence between the modulator and the surrogate agonist relative to the therapeutically relevant endogenous agonist. These considerations also extend to the potential for off-target activities of allosteric modulators. Although the aforementioned mAChR allosteric ligand 11 is a selective PAM for the M 4 mAChR when tested against ACh, it displays remarkable positive and negative allosteric effects at the M 2 mAChR when tested against other orthosteric agonists, such as oxotremorine and xanomeline. If the latter agents were used as surrogates to characterize mAChR activity in modulator screens, then the resultant pharmacology would reflect activity at an undesired target (e.g., M 2 mAChR) in addition to the desired target (e.g., M 4 mAChR). 90 Finally, there are many 7TMRs that have more than one endogenous orthosteric agonist but that may not all respond the same way to allosteric ligands. A striking example of this phenomenon was recently observed at the glucagon-like peptide 1 (GLP1) receptor, where the small molecule allosteric agonist 13 (Novo Nordisk's compound 2) had no effect on the signaling of the endogenous orthosteric peptide agonist GLP1(7−36) but significantly potentiated the signaling of another endogenous GLP1 receptor peptide, oxyntomodulin ( Figure 3 ). As a final point, when an allosteric ligand binds to a 7TMR, the receptor adopts a unique, novel conformation (vide infra), enabling it to activate any number of downstream signaling cascades to the exclusion of other possible receptor states.
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4−8,10,11 Here, probe dependence manifested at the level of the cytosolic interacting protein (e.g., G protein; β-arrestin, etc.) would result in signal pathway-dependent allosteric modulation. This has been coined "stimulus bias", "stimulus trafficking", "differential receptor trafficking", or "functional selectivity". 185−187 In short, an allosteric ligand may activate all downstream signaling cascades or a "surgical" selection of cascades with clear ramifications in pharmacodynamic models; therefore, it is critical to possess the requisite assays to understand how an allosteric ligand will modulate multiple signaling events. For example, the mGlu 5 PAM 14 (CPPHA, family C 7TMR) was shown to have differential effects on DHPGmediated calcium signaling and ERK1/2 phosphorylation in a native astrocyte system. 188 In addition, an allosteric modulator of the M 1 muscarinic receptor 15 (VU0029767) potentiates ACh-mediated intracellular calcium mobilization but not phospholipase D activation; therefore, depending on the pathway/ assay assessed, 15 would alternatively be classed as a PAM or a SAM, respectively (Figure 3) . 82 
MODE OF ACTION OF ALLOSTERIC MODUALTORS
7TMRs are highly flexible proteins capable of assuming multiple conformations, of which some are active, some are inactive (pharmacologically silent), and some are partially active. In fact, 7TMRs should be thought of as ensembles of tertiary conformations randomly sampled by the receptor, and very subtle changes (as small as 1 Å) can engender profound effects on receptor activity.
1,4−8,10,11 Thus, when an allosteric modulator binds to a site topographically distinct from the orthosteric site, a change in receptor conformation occurs that can modify receptor activity in a positive, negative, or neutral direction. As mentioned before, the allosterically bound receptor is a "new" receptor type, with novel behavior and activity potential. Oligomerization of GPCRs, as either heteroor homodimers, adds additional opportunities for modulation and probe dependence. 189 Operationally, 7TMR allosteric modulators exhibit affinity modulation, efficacy modulation, or varying degrees of both modes of modulation ( Figure 4A ).
With affinity modulation, the conformational change in the 7TMR upon allosteric ligand binding can affect either the association or dissociation rate (or both) of the orthosteric ligand.
1,4−8,10,11 For example, a PAM that displays affinity modulation will result in a more potent orthosteric ligand (agonist). For efficacy modulation, the conformational change in the 7TMR upon allosteric ligand binding leads to a change in signaling capacity (also termed intrinsic efficacy) and thereby either facilitates or inhibits receptor coupling to downstream effectors. There are two models proposed to account for the interactions between the allosteric and orthosteric ligand ( Figure 4B and Figure 4C) . 1, 4, 7 In one model, termed the "allosteric hot wire", the allosteric modulation site is directly linked to the orthosteric site through specific pathways. 1, 190, 191 In a more recent model, termed "global allosteric modulation", allosteric communication to the orthosteric site relies on longrange interaction through order/disorder transitions from multiple receptor conformations (i.e., population dynamics). 192, 193 A number of mass-action schemes, based on variants of the ternary complex model, have been presented to describe the molecular effects of allosteric ligands on orthosteric pharmacology in terms of one or more "cooperativity factors", which indicate the magnitude and direction of an allosteric modulatormediated stabilization of different 7TMR states.
4 From these models, it can be appreciated that the functional potency of an allosteric modulator will depend not only on its affinity for the allosteric site but also on the degree of cooperativity with the orthosteric ligand. Thus, a PAM (e.g., 11) may bind to the receptor with weak affinity but possess potent functional activity due to a high cooperativity factor. 4, 10, 90 In contrast, another PAM (e.g, benzodiazepines) may bind with very high affinity but low positive cooperativity, thus also displaying potent functional activity. The low affinity observed with some PAMs can preclude them from serving as radioligands and PET tracers, and the affinity/functional activity balance must be carefully assessed when considering receptor occupancy, for example, as a potential biomarker strategy.
Unfortunately, most mass-action-based molecular models of allosteric modulation contain too many parameters to be fitted to real experimental data and thus cannot be used to rationalize structure−activity studies in a manner that can inform drug candidate selection matrices. A useful means for placing these issues on a more practical quantitative level is through the use of an "operational" model of allosterism and agonism, which has been developed to describe allosteric effects in terms of a minimum number of experimentally accessible parameters. 194 This model is illustrated conceptually in (Figure 5 ), and the equation describing the signaling of an orthosteric agonist in the presence of an allosteric modulator according to the model is as follows:
where E is the effect, [A] and [B] are the concentrations, K A and K B are the equilibrium dissociation constants of the orthosteric and allosteric ligand, respectively, α is the cooperativity factor describing the allosteric effect of each ligand on the other's binding affinity, β is a scaling factor (from zero to infinity) that quantifies the magnitude by which the allosteric modulator modifies the efficacy of the orthosteric agonist at a given signal pathway, and the parameters τ A and τ B relate to the ability of the orthosteric and allosteric ligands, respectively, to promote receptor activation (direct agonism). These latter parameters incorporate the intrinsic efficacy of each ligand, the total density of receptors, and the efficiency of stimulus-response coupling. The parameters E m and n denote the maximal possible system response and the slope factor of the transducer function that links occupancy to response, respectively.
4, 10, 194 Importantly, the operational model can be fitted to experimentally derived data to provide estimates of some, or all, of its parameters. 47,52,90,195−197 At a minimum, there are three key parameters that can be routinely derived from application of this model to most functional screening data, as long as full concentration response and curve-shift relationships are determined. These three parameters are the allosteric modulator K B , which provides information on the interaction of the allosteric ligand with the allosteric binding pocket on the free receptor, the composite cooperativity parameter αβ, which provides information on the overall allosteric effect on the orthosteric agonist in the chosen functional assay, and the modulator efficacy parameter τ B , which provides information on the ability of the allosteric ligand to promote agonism in its own right in the absence of orthosteric ligand. Table 4 illustrates an example of such allosteric modulator SAR determined through analysis of the functional effects of a series of 2-amino-3-benzoylthiophenes (2A3BT) on A 1 adenosine receptor-mediated ERK1/2 phosphorylation. 46 From this analysis, it can be seen that the increase in trifluoromethylphenyl substitutions to the R 2 group of the 2A3BT scaffold can increase positive cooperativity while having a detrimental effect on modulator affinity (compare 16b to 16d, and 16g to 16h), whereas conformational constraint in the R 2 /R 3 regions tends to convert positive modulators into highly negative modulators (e.g., 16n, 16r). It is also noted that the reference compound, 16a, progressed into phase IIB clinical trials for the treatment of neuropathic pain (King Pharmaceuticals) prior to failing due to lack of efficacy; it is possible that this failure may be attributed to the rather low degree of positive cooperativity, as revealed by the application of the operational model to the in vitro data. Although speculative, this finding highlights some of the advantages of operational modeling when applied to allosteric SAR, namely, the ability to link the chemistry to the key, measured biological parameters and the ability to facilitate hypothesis generation to understand biological mechanisms and their relevance to the desired therapeutic profile. For instance, one can ask questions such as the following: How much cooperativity (αβ) or allosteric agonism (τ B ) is required to achieve in vivo efficacy? How do structural modifications affect compound affinity (K B ) versus cooperativity (αβ)? The latter is important because these properties are not correlated, and thus, different structural manipulations can change them in different directions. Probe dependence will manifest as different αβ values depending on the orthosteric agonist used and/or the signal pathway being assessed as a readout of receptor activation. In terms of drug discovery programs, these insights can be used to more rationally inform the design of candidate selection matrices for drugs acting allosterically. 46,47,52,90,195−197 3. IN VITRO PHARMACOLOGY OF ALLOSTERIC MODULATORS The development of high-throughput functional (kinetic) assays have enabled scientists to perform screens of large compound collections and to identify small molecules capable of modulating the activity of a receptor through novel, allosteric mechanisms.
4, 160,198−201 While there are multiple approaches and technologies to accomplish this for 7TMRs, one of the most common approaches measures receptor-induced mobilization of intracellular calcium using an imaging-based plate reader that makes simultaneous measurements of calcium levels in each well of a multiwell microplate containing cells transfected with the receptor of interest and loaded with calcium-sensitive fluorescent dye. In the early stages of drug discovery for allosteric modulators of 7TMRs, HTS campaigns targeted the identification of either PAMs or NAMs, running single-point screens with either an EC 20 or EC 80 concentration of the orthosteric agonist, respectively. More recently, "triple add" protocols have supplanted "single add" screens to allow for, in a single assay, the identification of PAMs, NAMs, agonists, and antagonists ( Figure 6A) . 4,160,198−201 Because of Figure 6 . Functional assays, measuring calcium fluorescence as a surrogate for 7TMR receptor activation, employed to identify and profile 7TMR allosteric modulators. (A) "Triple add" paradigm for both HTS campaigns and primary assay for lead optimization: vehicle (black) trace where an EC 20 of orthosteric agonist is added 150 s into the kinetic run, followed by an EC 80 of orthosteric agonist. Compounds are added at T = 0, and an agonist (green) elicits calcium fluorescence immediately upon addition. Secondary assays with orthosteric radioligands and/or mutant receptors will determine if the compound is an orthosteric or allosteric agonist. An antagonist (red) will block both the EC 20 and the EC 80 ; once again, secondary assays will distinguish competitive from noncompetitive (NAM) antagonists. A pure PAM (blue) will not elicit receptor activation alone but will potentiate the EC 20 to varying degrees of efficacy, while an ago-PAM (orange) will activate the receptor alone, plus potentiate the EC 20 . Hence, a single assay protocol will identify agonists, allosteric agonists, PAMs, ago-PAMs, antagonists, and NAMs. (B) In vitro pharmacology of an mAChR PAM, once again with a calcium fluorescence readout. The PAM has no effect alone on receptor activation, but in the presence of an EC 20 (or subthreshold concentration of orthosteric agonist, ACh in this case), a classical concentration−response curve (CRC) results, from which an EC 50 for potentiation can be calculated. Also, the %Max, the degree of potentiation above the EC 20 , can be measured, and both the EC 50 and %Max must be optimized. (C) "Fold shift" assay. Here, the concentration of the orthosteric agonist (ACh) is held constant, and increasing concentrations of the PAM cause a parallel leftward shift of the ACh CRC, in effect making ACh a more potent agonist.
the emerging concept of "molecular switches" (see below), 202 this screening paradigm is also optimal for use as a program's primary assay to identify subtle structural changes leading to opposing modes of pharmacology. As shown in Figure 6B , a prototypical PAM has no effect on the transfected cells in the absence of the orthosteric agonist, but in the presence of a subthreshold concentration of the orthosteric agonist, increasing PAM concentrations provide a classical concentration−response curve (CRC) from which an EC 50 for potentiation can be quantified as an empirical measure of modulator potency under a defined set of assay conditions. 4, 5 This also affords a %Max value, the maximum increase in activity of the orthosteric agonist above the EC 20 , i.e., from an EC 20 to an EC 80 . In this type of experimental paradigm, the observed EC 50 reflects both the affinity of the modulator for the allosteric site and the degree of cooperativity that it exerts on the orthosteric ligand. In contrast, the %Max only reflects the cooperativity of the interaction. Each of these parameters must be optimized, as it is possible to have allosteric modulators with high potency and low %Max (reflecting high affinity and low cooperativity), weak potency and high %Max (low affinity and high cooperativity), and various combinations thereof. If the assay is run in an alternative mode, whereby the complete orthosteric agonist CRC is determined in the absence or presence of a fixed concentration of allosteric modulator, then another property that can be evaluated and optimized is the degree of the agonist curve "fold shift", either to the left (potentiation) or right/down (antagonism) of an agonist CRC ( Figure 6C) . 4 ,5 This is typically reported as a fold shift at a single concentration, such as a 30-fold shift at 10 μM. Optimally, if multiple modulator concentrations are utilized in this latter type of experiment, then the data can be fitted to the operational model (above) and direct estimates of affinity and cooperativity can be obtained. Irrespective, each of the properties described in the preceding section (%Max, potency, fold shift or operational model affinity, cooperativity, and efficacy) must be simultaneously optimized for optimal in vivo efficacy.
4,5 A common question posed in small molecule allosteric modulators programs is the follwing: Which of these parameters is most important for in vivo efficacy? Unfortunately, the answer is not clear and may vary by 7TMR, allosteric binding site, allosteric ligand chemotype, and therapeutic indication. For now, a general empirical guideline followed by most researchers in the field is to optimize for potency (EC 50 ) and %Max and aim for at least a 5-fold shift of the agonist CRC; however, estimates of fold shift for some family A and family C 7TMR allosteric ligands may approach >70-fold, depending on the assay.
4,5
Other properties of a CNS compound, for example, the ability of a compound to penetrate the blood−brain barrier, the clearance of a compound from the brain and systemic compartments, the amount of compound that is non-protein bound and able to interact with the target, and the in vivo situation being assessed (for example, how long does a receptor need to be occupied with drug to maintain efficacy), certainly must be balanced with in vitro pharmacology profiles when assessing in vivo efficacy and potency of allosteric modulators.
STRUCTURE−ACTIVITY RELATIONSHIPS (SARS)
WITHIN mGluRs AND mAChRs Another common observation from numerous structure− activity relationship (SAR) studies performed to date on 7TMR allosteric modulators is the finding of "flat" or "shallow" SAR for different classes, often making optimization of micromolar potency ligands either difficult or impossible.
1,4−12 The literature in this arena is filled with tales of heroic optimization campaigns wherein hundreds or thousands of compounds were synthesized and evaluated, affording only 5−10% active molecules. However, there are also cases wherein SAR is robust and tractable, though rare. Thus, for the chemical optimization of allosteric ligands, 4, 197, 202 focused, iterative library synthesis provides a distinct advantage over traditional singleton approaches; however, multiple dimensions of a scaffold must be surveyed to identify regions tolerant of modification. As SAR is often extremely "shallow", the concept of walking fluorine atoms around an allosteric ligand, i.e., "the fluorine walk", has achieved some success in identifying positions tolerant of change. For example, 6 displayed "shallow" SAR, and multiple attempts at optimization, adding groups larger than fluorine (methyl, OR, Cl, Br, alkyl, etc.) to multiple positions (i.e., R 1 and/or R 2 ) on the scaffold of 6, led to primarily inactive compounds 17. 33, 203 The strategic installation of fluorine atoms to both the core R 1 and the benzyl side chain R 2 of 6 led to compounds with significant improvements in M 1 PAM activity ( A very similar "fluorine walk" strategy has proven successful in developing submicromolar M 1 PAMs in other chemotypes. 83, 84 It is important to note that in these cases and many other published studies, only fluorine substitutions were tolerated, making this approach a potential first tier strategy in allosteric ligand optimization.
In addition to the "flat" or "shallow" allosteric structure− activity relationships (SAR), the emerging concept of "molecular switches", i.e., subtle structural changes that can change the mode of pharmacology (from PAM to NAM and/or SAM) and/or subtype selectivity within a family of receptors, threatens to diminish the application of rational drug design approaches to allosteric modulators. 202 Moreover, unexpected occurrences of "molecular switches" require alterations to routine screening paradigms for optimization efforts. Here, the "triple add" approach is ideal, 4,160,198−201 identifying allosteric agonists, PAMs, and NAMs in a single screen. Although examples of "molecular switches" developed for mGluRs and mAChRs are presented herein, this subtle effect has been reported for allosteric kinase and phospholipase ligands as well. 202 In the field of mGluRs, the first allosteric modulators disclosed were (−)-ethyl (7E)-7-hydroxyimino-1,7α-dihydrocyclopropa[b]chromene-1α-carboxylate (CPCCOEt, mGlu 1 selective) and 10 (mGlu 5 selective), both NAMs, followed by the earliest mGlu 5 PAMs, 3,3′-difluorobenzaldazine (DFB), 14, and 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB).
4,44 While various molecular switches on the difluorobenzaldazine scaffold had the ability to engender the full range of PAM, NAM, and SAM pharmacology (structures not shown), 161 an even more surprising example of pharmacological mode switching can be seen in Figure 8 . A functional HTS with the mGlu 5 receptor identified the "partial antagonist" 22, which maximally inhibited 71% of the glutamate response with mGlu 5 IC 50 = 486 nM. 202,204−206 This simple and very low molecular weight hit was rapidly explored using a parallel iterative library approach to reveal numerous molecular switches. Introduction of a 3′-methyl group transformed the partial antagonist into a very potent full NAM 23 (mGlu 5 IC 50 = 7.5 nM). This methyl group exquisitely illustrates the idea of a "molecular switch" as it is moved just one position over to provide compound 24, which is now a weak PAM (mGlu 5 EC 50 = 3.3 μM) with the ability to potentiate a submaximal dose of glutamate up to a full glutamate response (99% Glu Max). Further optimization within this series of PAMs provided compound 25, a very potent mGlu 5 PAM that possessed robust in vivo efficacy in a rodent amphetamineinduced hyperlocomotion assay. 202,204−206 Also within the mGluR field, molecular switches have been reported that profoundly affect the receptor subtype selectivity of a given allosteric ligand and also the mode of pharmacology. Figure 9 shows 26 ((−)-PHCCC), which possess both mGlu 4 PAM and mGlu 1 NAM activity. 155 Introduction of a weakly basic nitrogen to arrive at 27 (VU0359516) effectively abolished all mGlu 1 NAM activity to provide a pure mGlu 4 PAM (EC 50 > 30 μM versus mGlu 1−3,5−8 ) with good potency and efficacy (mGlu 4 EC 50 = 380 nM, Glu Max = 121%, 20-fold shift). 155 Subsequent to this work, an mGlu 2 FRET-based binding assay identified the fluorinated analogue 28 which displayed mGlu 2 K i = 6.6 μM while at the same time lacked all functional activity at mGlu 2 and mGlu 3 . 207 Importantly, 28 could also block (silence) the activities of related mGlu 2 and mGlu 3 allosteric modulators 29−31, the definition of an mGlu 2/3 SAM. As alluded to above, the position of the fluorine in 28 represented a productive location for the introduction of alternate molecular switches ( Figure 9 , X = Cl, Me, OMe) which could transform an mGlu 1 NAM/mGlu 4 PAM 26 or an mGlu 2/3 SAM 28 into a series of mGlu 2 NAM/mGlu 3 PAMs 29−31.
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These types of molecular switches that govern receptor subtype selectivity have similarly been reported in the mAChR literature. Figure 10 shows 32, which was an attractive, lowmolecular weight PAM hit from a functional HTS assay with the M 1 mAChR. 82,84,94−96 Although originally identified as only an M 1 PAM, subsequent characterization revealed 32 to be a nonselective G q -coupled mAChR PAM displaying activity at the M 1,3,5 receptor subtypes while being devoid of activity at the G i -coupled M 2 and M 4 mAChRs. 82 This interesting selectivity for the different G-protein-coupled signaling pathways spurred medicinal chemistry efforts to determine if subtle molecular switches could be discovered that might provide selectivity for a single mAChR subtype. The first breakthrough came with the discovery that placing a 5-trifluoromethoxy substituent on the isatin core led to a profound preference for M 5 PAM activity. This molecular switch employed during an exploration of substituents about the benzyl group ultimately provided 33 (R = Me, ML129) and 34 (R = Ph, ML172), the first and most highly selective M 5 PAMs, respectively, reported to date. 94−96 Further structural modifications around the nonselective lead 32 revealed that replacing the bromine with various aryl groups identified the N-methylpyrazole as a powerful molecular switch for establishing high levels of M 1 selectivity. Fine-tuning this M 1 PAM activity through the strategic introduction of a fluorine atom, i.e., the "fluorine walk", provided the highly selective M 1 PAM 35 (ML137). 84 Ongoing studies exploring the utility of these and other allosteric ligands promise to reveal numerous additional molecular switches, and as these compounds progress into more animal models and detailed DMPK evaluations, it will only be a matter of time before metabolisminduced molecular switches are reported. 201 Such molecular switches may not be observed within all allosteric ligand scaffolds or at all allosteric binding sites; in fact, some allosteric ligands and binding sites are considered "molecular locks" with robust tractable SAR.
OPPORTUNITIES FOR CNS DISORDERS AND THERAPEUTICS
Despite these challenges, allosteric ligands have enabled researchers to develop small molecule tools (Tables 1−3) 4−8, 10,11,42−180 with exquisite selectivity for a particular target, not possible with orthosteric ligands, and to achieve proof of concept in preclinical models of various CNS disorders. For example, mGlu 5 NAMs have provided preclinical target validation in models of anxiety, fragile X syndrome, chronic pain, migraine, and GERD. 170 In fact, mGlu 5 NAMs are one of the most advanced with multiple compounds in clinical development and displaying efficacy in phase II (Table 5) . 208 The biogenic amine receptors, the prototypes for promiscuous pharmacology, have benefited greatly from allosteric approaches.
4,42−180 For example, the mAChRs have been targets of interest for multiple CNS disorders since the 1950s, but the highly conserved orthosteric (acethycholine) binding site led to unselective small molecules. Because of the therapeutic relevance of the mAChRs, multiple companies advanced orthosteric pan-mAChR agonists into the clinic and noted efficacy in phase II and phase III trials in Alzheimer's disease and schizophrenia patients; however, the adverse events from activation of peripheral M 2 and M 3 prevented further development. Recently, allosteric ligands, both allosteric/ bitopic agonists and PAMs, have been developed for M 1 , M 4 , and M 5 . 4, 43 These tools are now dissecting the individual contributions of these three mACh receptor subtypes in the clinical efficacy of pan-mAChR agonists. Importantly, this is but one example against the backdrop of the allosteric ligands in Tables1−3, 4,42−180 that are validating discrete targets within large families of receptors and shedding light on the therapeutic potential of GPCRs, long obscured by the lack of selective tool compounds.
Finally, it is very important to point out that allosteric ligands have been advanced into marketed therapeutics, suggesting that the approach of targeting allosteric mechanisms is sound and tractable ( Figure 11 ). 36 is a PAM of the calcium sensing receptor (a family C GPCR) and is used to treat hyperparathyroidism. 115 37 is a NAM of chemokine receptor 5 (a family A GPCR) that inhibits HIV entry into cells and is used to treat HIV infections. 72 Thus, both PAMs and NAMs have advanced to the market, with many other allosteric ligands in clinical trials and late preclinical development. 
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CONCLUSION
The broad uptake of the concept of allosteric modulation has led to a renaissance in pharmacological approaches toward 7TMR pharmacology, promising new and exciting avenues to the pursuit of receptor-subtype and pathway-selective small molecules. Although the promises of this approach are apparent, there remain significant challenges with regard to optimal means for detecting, validating, and quantifying allosteric ligand effects in a manner that routinely informs SAR and candidate selection matrices and is also ultimately predictive of therapeutic efficacy. To meet these challenges, further convergence is required between the disciplines of pharmacology, which can shed insight into the nature and mechanisms underlying phenomena such as probe dependence and pathway-biased modulation, medicinal/synthetic chemistry, which can overcome the issue of "flat" allosteric SAR and explore the full potential of molecular switches in creating new allosteric behaviors, and structural biology, which can identity the underlying structural basis of allosteric ligand binding and the associated receptor conformations that mediate allosteric effects. Fortunately, recent work in the field is illustrating how truly translational approaches toward 7TMR pharmacology promise to overcome many of these challenges and to realize the therapeutic potential of allosteric modulators as novel medicines. 
